Class information for: |
Basic class information |
Class id | #P | Avg. number of references |
Database coverage of references |
---|---|---|---|
1615 | 2567 | 28.8 | 66% |
Hierarchy of classes |
The table includes all classes above and classes immediately below the current class. |
Cluster id | Level | Cluster label | #P |
---|---|---|---|
6 | 4 | GASTROENTEROLOGY & HEPATOLOGY//ONCOLOGY//SURGERY | 1371034 |
112 | 3 | CERVICAL CANCER//HUMAN PAPILLOMAVIRUS//GYNECOLOGIC ONCOLOGY | 70812 |
185 | 2 | OVARIAN CANCER//GYNECOLOGIC ONCOLOGY//OVARIAN NEOPLASMS | 21857 |
1615 | 1 | OVARIAN CANCER//RECURRENT OVARIAN CANCER//PEGYLATED LIPOSOMAL DOXORUBICIN | 2567 |
Terms with highest relevance score |
rank | Term | termType | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|---|
1 | OVARIAN CANCER | authKW | 493847 | 27% | 6% | 697 |
2 | RECURRENT OVARIAN CANCER | authKW | 362370 | 3% | 38% | 80 |
3 | PEGYLATED LIPOSOMAL DOXORUBICIN | authKW | 265992 | 3% | 29% | 77 |
4 | PLATINUM RESISTANT | authKW | 260644 | 2% | 55% | 40 |
5 | TOPOTECAN | authKW | 255230 | 5% | 16% | 134 |
6 | CARBOPLATIN | authKW | 214517 | 8% | 8% | 216 |
7 | GYNECOLOGIC ONCOLOGY | journal | 206877 | 17% | 4% | 444 |
8 | PLATINUM SENSITIVE | authKW | 171041 | 1% | 55% | 26 |
9 | RELAPSED OVARIAN CANCER | authKW | 156230 | 1% | 77% | 17 |
10 | ADVANCED OVARIAN CANCER | authKW | 113211 | 2% | 24% | 40 |
Web of Science journal categories |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | Oncology | 65641 | 81% | 0% | 2080 |
2 | Obstetrics & Gynecology | 34999 | 35% | 0% | 909 |
3 | Radiology, Nuclear Medicine & Medical Imaging | 128 | 4% | 0% | 104 |
4 | Medicine, General & Internal | 94 | 5% | 0% | 118 |
5 | Pharmacology & Pharmacy | 56 | 6% | 0% | 143 |
6 | Hematology | 13 | 2% | 0% | 40 |
7 | AGRICULTURAL EXPERIMENT STATION REPORTS | 9 | 0% | 0% | 1 |
8 | Transplantation | 4 | 1% | 0% | 17 |
9 | Health Care Sciences & Services | 3 | 1% | 0% | 17 |
10 | Health Policy & Services | 1 | 0% | 0% | 9 |
Address terms |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | GYNECOL ONCOL | 72364 | 10% | 2% | 261 |
2 | GYNECOL ONCOL GRP | 35746 | 1% | 10% | 30 |
3 | CLEVELAND CLIN TAUSSIG CANC R35 | 35681 | 0% | 100% | 3 |
4 | HEMATOL MED ONCOL R35 | 26759 | 0% | 75% | 3 |
5 | OVARIAN CANC ACT HHMT | 26759 | 0% | 75% | 3 |
6 | GILLETTE WOMENS STUDIES | 23787 | 0% | 100% | 2 |
7 | LAKESIDE VA MED | 23787 | 0% | 100% | 2 |
8 | ONCOL CHIRURG GINECOL | 23787 | 0% | 100% | 2 |
9 | OVAR | 23787 | 0% | 100% | 2 |
10 | GYNECOL GYNECOL ONCOL | 15387 | 1% | 6% | 21 |
Journals |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | GYNECOLOGIC ONCOLOGY | 206877 | 17% | 4% | 444 |
2 | INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 99546 | 8% | 4% | 193 |
3 | SEMINARS IN ONCOLOGY | 31709 | 5% | 2% | 118 |
4 | ANNALS OF ONCOLOGY | 21409 | 5% | 1% | 122 |
5 | JOURNAL OF CLINICAL ONCOLOGY | 13640 | 5% | 1% | 137 |
6 | OHIO AGRICULTURAL RESEARCH AND DEVELOPMENT CENTER DEPARTMENT SERIES ESS | 11894 | 0% | 100% | 1 |
7 | EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY | 8543 | 2% | 2% | 46 |
8 | AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS | 7601 | 2% | 1% | 51 |
9 | ONCOLOGY | 5527 | 2% | 1% | 43 |
10 | ONKOLOGIE | 4946 | 1% | 1% | 33 |
Author Key Words |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | OVARIAN CANCER | 493847 | 27% | 6% | 697 | Search OVARIAN+CANCER | Search OVARIAN+CANCER |
2 | RECURRENT OVARIAN CANCER | 362370 | 3% | 38% | 80 | Search RECURRENT+OVARIAN+CANCER | Search RECURRENT+OVARIAN+CANCER |
3 | PEGYLATED LIPOSOMAL DOXORUBICIN | 265992 | 3% | 29% | 77 | Search PEGYLATED+LIPOSOMAL+DOXORUBICIN | Search PEGYLATED+LIPOSOMAL+DOXORUBICIN |
4 | PLATINUM RESISTANT | 260644 | 2% | 55% | 40 | Search PLATINUM+RESISTANT | Search PLATINUM+RESISTANT |
5 | TOPOTECAN | 255230 | 5% | 16% | 134 | Search TOPOTECAN | Search TOPOTECAN |
6 | CARBOPLATIN | 214517 | 8% | 8% | 216 | Search CARBOPLATIN | Search CARBOPLATIN |
7 | PLATINUM SENSITIVE | 171041 | 1% | 55% | 26 | Search PLATINUM+SENSITIVE | Search PLATINUM+SENSITIVE |
8 | RELAPSED OVARIAN CANCER | 156230 | 1% | 77% | 17 | Search RELAPSED+OVARIAN+CANCER | Search RELAPSED+OVARIAN+CANCER |
9 | ADVANCED OVARIAN CANCER | 113211 | 2% | 24% | 40 | Search ADVANCED+OVARIAN+CANCER | Search ADVANCED+OVARIAN+CANCER |
10 | PACLITAXEL | 88952 | 8% | 4% | 214 | Search PACLITAXEL | Search PACLITAXEL |
Core articles |
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c: (1) Number of references referring to publications in the class. (2) Share of total number of active references referring to publications in the class. (3) Age of the article. New articles get higher score than old articles. (4) Citation rate, normalized to year. |
Rank | Reference | # ref. in cl. |
Shr. of ref. in cl. |
Citations |
---|---|---|---|---|
1 | MARTIN, LP , SCHILDER, RJ , (2009) MANAGEMENT OF RECURRENT OVARIAN CARCINOMA: CURRENT STATUS AND FUTURE DIRECTIONS.SEMINARS IN ONCOLOGY. VOL. 36. ISSUE 2. P. 112-125 | 91 | 84% | 45 |
2 | DU BOIS, A , LUCK, HJ , BAUKNECHT, T , PFISTERER, J , MEIER, W , (2000) SECOND-LINE CHEMOTHERAPIE AFTER PLATINUM OR PLATINUM AND PACLITAXEL-BASED CHEMOTHERAPY FOR OVARIAN CANCER: A SYSTEMATIC REVIEW.GEBURTSHILFE UND FRAUENHEILKUNDE. VOL. 60. ISSUE 1. P. 41 -58 | 128 | 81% | 9 |
3 | HOGBERG, T , GLIMELIUS, B , NYGREN, P , (2001) A SYSTEMATIC OVERVIEW OF CHEMOTHERAPY EFFECTS IN OVARIAN CANCER.ACTA ONCOLOGICA. VOL. 40. ISSUE 2-3. P. 340 -360 | 108 | 82% | 57 |
4 | BOERE, IA , VAN DER BURG, MEL , (2012) REVIEW OF DOSE-INTENSE PLATINUM AND/OR PACLITAXEL CONTAINING CHEMOTHERAPY IN ADVANCED AND RECURRENT EPITHELIAL OVARIAN CANCER.CURRENT PHARMACEUTICAL DESIGN. VOL. 18. ISSUE 25. P. 3741 -3753 | 64 | 74% | 8 |
5 | GOCHEVA, L , (2009) WHOLE ABDOMEN IRRADIATION IN EPITHELIAL OVARIAN CANCER - STATE OF THE ART.WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY. VOL. 13. ISSUE 4. P. 181 -190 | 67 | 78% | 0 |
6 | HERZOG, TJ , (2004) RECURRENT OVARIAN CANCER: HOW IMPORTANT IS IT TO TREAT TO DISEASE PROGRESSION?.CLINICAL CANCER RESEARCH. VOL. 10. ISSUE 22. P. 7439-7449 | 63 | 84% | 70 |
7 | MARKMAN, M , (2008) PHARMACEUTICAL MANAGEMENT OF OVARIAN CANCER - CURRENT STATUS.DRUGS. VOL. 68. ISSUE 6. P. 771 -789 | 92 | 47% | 65 |
8 | THIGPEN, T , (2006) THE ROLE OF GEMCITABINE IN FIRST-LINE TREATMENT OF ADVANCED OVARIAN CARCINOMA.SEMINARS IN ONCOLOGY. VOL. 33. ISSUE 2. P. S26-S32 | 54 | 96% | 5 |
9 | SEHOULI, J , OSKAY-OZCELIK, G , (2009) CURRENT ROLE AND FUTURE ASPECTS OF TOPOTECAN IN RELAPSED OVARIAN CANCER.CURRENT MEDICAL RESEARCH AND OPINION. VOL. 25. ISSUE 3. P. 639 -651 | 45 | 92% | 15 |
10 | PECTASIDES, D , PSYRRI, A , PECTASIDES, M , ECONOMOPOULOS, T , (2006) OPTIMAL THERAPY FOR PLATINUM-RESISTANT RECURRENT OVARIAN CANCER: DOXORUBICIN, GEMCITABINE OR TOPOTECAN?.EXPERT OPINION ON PHARMACOTHERAPY. VOL. 7. ISSUE 8. P. 975-987 | 56 | 79% | 11 |
Classes with closest relation at Level 1 |